We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Self-Collection Medical Test Makes HPV Screening Easier for Patients

By LabMedica International staff writers
Posted on 09 Jan 2025

Human papillomavirus (HPV) is the most prevalent sexually transmitted infection (STI) in the U. More...

S. HPV spreads through skin-to-skin contact, typically during sexual activity with someone who carries the virus. There are over 200 types of HPV, but not all lead to cancer, including cervical cancer. Certain high-risk types of HPV can evade the immune system and persist in the body, damaging cells and potentially causing them to become cancerous. If cervical cancer is detected early, it can be completely cured. However, if diagnosed later, cervical cancer is much harder to treat and often incurable. Pap tests enable the detection of precancerous changes in the cervix, which can be treated to prevent cancer. HPV is a key indicator of these changes, and precancerous conditions rarely develop without the presence of HPV. Traditional cervical cancer screenings are performed during pelvic exams. At present, there is no standard medical test for high-risk HPV. However, there are various tests where patients collect their own samples, such as nasal swabs for COVID-19, urine samples for pregnancy, and stool tests for colorectal cancer. Now, tests for high-risk HPV, which can lead to cervical cancer, have also been added to this list.

In December, the U.S. Preventive Services Task Force released new draft guidelines recommending that women may self-collect vaginal samples for HPV testing during visits to their clinician. Experts believe this approach could increase screening rates and lead to earlier detection of cervical precancers and cancers. In May, the Food and Drug Administration (FDA) approved self-collection kits for use in a clinician’s office. The approved tests include Onclarity HPV from Becton, Dickinson and Company (BD, Franklin Lakes, NJ, USA) and cobas HPV from Roche Molecular Systems (Basel, Switzerland). These tests are similar to those used by gynecologists to screen for high-risk HPV and have shown to be very effective. Since the kits currently approved by the FDA are for collection in a clinician’s office, most patients will likely obtain them from their primary care provider. The patient is provided with an instruction sheet and a collection swab for insertion into the vagina. Afterward, the patient goes into a restroom to collect their sample and returns it to the clinician, who then sends it to a lab for analysis. In the future, self-collection from home may also become an option.

These tests make HPV screening significantly more accessible for patients who may not be able—or willing—to see a gynecologist for various reasons. Some may lack access to a gynecologist, have experienced trauma that makes pelvic exams particularly difficult, or have hectic schedules that cause them to continually delay their visit. If they visit their primary care provider, they can perform an HPV test right then. If the result is negative—indicating no HPV present—they will not need another cervical cancer test for five years. If the result is positive, they need to follow up with a gynecologist for further screening. Experts believe these tests will boost screening rates, help identify individuals with high-risk HPV, and reduce deaths from cervical cancer.

“I think this testing is going to make it much easier for women to ensure they are up to date with cervical cancer screening, said Caroline Goldzweig, MD, chief medical officer of Cedars-Sinai Medical Network. “Many women see primary care physicians who may not routinely perform pelvic exams, and having to make a separate visit to a gynecologist can be a barrier for patients. Cervical cancer is so preventable, given what we now know about how to manage early abnormalities, that every case is a tragedy.”

Related Links:
BD 
Roche


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Collection and Transport System
PurSafe Plus®
New
Laboratory Software
ArtelWare
New
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Left is the original cell image and right is same cell image zoomed in and rendered in the special imaging software (Photo courtesy of FIU)

Brain Inflammation Biomarker Detects Alzheimer’s Years Before Symptoms Appear

Alzheimer’s disease affects millions globally, but patients are often diagnosed only after memory loss and other symptoms appear, when brain damage is already extensive. Detecting the disease much earlier... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.